RO4917838 + rosuvastatin

**RO4917838 + rosuvastatin** is an experimental drug combination consisting of RO4917838 (also known as bitopertin), a glycine transporter type 1 (GlyT1, SLC6A9) inhibitor, and rosuvastatin, a statin drug used to lower cholesterol. RO4917838 increases glycine levels by blocking its reuptake, potentially enhancing NMDA receptor function, which is relevant for diseases like schizophrenia. Rosuvastatin is an HMG-CoA reductase inhibitor, primarily used to lower LDL cholesterol for cardiovascular risk reduction. This combination has been studied to evaluate pharmacokinetic interactions and safety in healthy volunteers but is not established for clinical use as a combination therapy.

Other names

bitopertin + rosuvastatin